The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma.

Abstract

PURPOSE:

To evaluate the short-term efficacy and safety of recombinant human endostatin (Endostar) combined with chemoradiotherapy for the treatment of advanced, locally recurrent nasopharyngeal carcinoma (NPC).

MATERIALS AND METHODS:

Between March 2010 and October 2013, a total of 22 patients with stage rIII-IVb locally recurrent NPC underwent salvage radiotherapy with Endostar in Sun Yat-Sen University Cancer Center. Intensity-modulated radiotherapy (IMRT) was delivered. Platinum-based chemotherapy was used in a neoadjuvant protocol. Endostar was continuously administered intravenously (105 mg/m2) for 14 days (Days 1-14) from the first day of treatment during a 21-day cycle. Tumor response and treatment toxicities were observed.

RESULTS:

Until January 2014, the median follow-up time was 13 months (range, 4-41 months). All patients completed the planned radiotherapy. A complete response was achieved in 20 patients, and a partial response was achieved in 2 patients. The incidence of grade 3-5 late radiation injury in this study was 50% (11/22) and that of nasopharyngeal mucosal necrosis was 31.8% (7/22).

CONCLUSIONS:

Endostar combined with chemoradiotherapy may be effective in decreasing both the incidence of nasopharyngeal mucosal necrosis. Studies with a larger sample size and longer follow-up are warranted.

• Authors: Ying Guan, Anchuan Li, Weiwei Xiao, Shuai Liu, Binbin Chen, Taixiang Lu, Chong Zhao, Fei Han
• Journal: Oncotarget (Oncotarget) Vol. 6 Issue 32 Pg. 33926-34 (Oct 20 2015) ISSN: 1949-2553 [Electronic] United States
• PMID: 26418895 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Endostatins
• Recombinant Proteins
• Cisplatin

Topics

• Adult
• Chemoradiotherapy (methods)
• Cisplatin (administration & dosage)
• Combined Modality Therapy
• Endostatins (administration & dosage)
• Female
• Follow-Up Studies
• Humans
• Incidence
• Infusions, Intravenous
• Male
• Middle Aged
• Nasopharyngeal Neoplasms (drug therapy, radiotherapy)
• Neoplasm Recurrence, Local
• Radiotherapy, Intensity-Modulated (methods)
• Recombinant Proteins (administration & dosage)
• Retrospective Studies
• Salvage Therapy (methods)
• Treatment Outcome